CLAIM CARD
The mechanistic evidence for rapamycin's lifespan effects is anchored in two preclinical studies from the NIA Interventions Testing Program. Translational relevance to humans remains uncertain. Extending this work, Miller 2014 demonstrated that rapamycin increased median lifespan of genetically heterogeneous mice by 23% in males to 26% in females when tested at a dose that was threefold lower than the original study. These findings establish a robust dose- and sex-dependent lifespan extension in a gold-standard preclinical model.
Evidence grade: exploratory
Contradiction status: none
Publication: f02d4a53-03e5-47ed-9876-75a416e3bd24
Provenance: Derivation Web chain
Citation Support
source_1Moel 2025source_2Gkioni 2025source_3Smiaek 2023source_4Willows 2023source_5Harinath 2025